Fifth Third Bancorp Acquires Stake in Lineage Cell Therapeutics
What happened
Fifth Third Bancorp acquired a new financial stake in Lineage Cell Therapeutics on October 16, 2026. On that day, Lineage Cell Therapeutics shares traded down 1.2% during mid-day trading, closing at $0.9783. The company had previously closed at $0.9903.
From dailypolitical.com
Why it matters
The investment occurred while Lineage Cell Therapeutics reported revenue of $1.07 million, missing the consensus estimate of $1.84 million. The company also reported a negative net margin of 246.58% for the quarter.
From dailypolitical.com
Who's involved
- Fifth Third BancorpAmerican bank holding company that acquired a new financial stake in Lineage Cell Therapeutics.
- Lineage Cell TherapeuticsBiotechnology company that received the new financial stake from Fifth Third Bancorp.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Lineage Cell TherapeuticsSpeculative
Lineage Cell Therapeutics might see its market price change due to the reported stock decline.
Keep exploring
The entities involved
-
Fifth Third Bancorp
American bank holding company
-
Lineage Cell Therapeutics
biotechnology company
Nothing else this week.
Related events
- Fifth Third Bancorp purchased a new position in the Advent Convertible and Income Fund on October 16, 2026.
- Fifth Third Bancorp purchased a new stake in the BlackRock MuniYield Quality Fund, Inc. on October 12, 2026.
- Fifth Third Bancorp purchased a new position in the First Trust Energy AlphaDEX Fund on July 2, 2026.
- Fifth Third Bancorp purchased a new stake in the Morgan Stanley Pathway Large Cap Equity ETF.
- Fifth Third Bancorp increased its stake in Crescent Energy Company on June 17, 2026.